To the Editor We congratulate Li et al for conducting a large-scale randomized clinical trial (RCT) evaluating geriatric assessment–driven intervention (GAIN) for older people with cancer.1 Because this study showed that GAIN significantly reduced the incidence of grade 3 or higher chemotherapy-related toxic effects, the results solidify the efficacy of the integration of multidisciplinary geriatric assessment (GA) intervention. However, as some other recent clinical trials have failed to show the efficacy of that,2,3 it is important to evaluate the results of this trial carefully. We thus have several concerns, especially regarding the study design.
Shimizu D, Takahashi M, Mizutani T. Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. JAMA Oncol. 2022;8(4):647. doi:10.1001/jamaoncol.2021.8064
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.